Latest Breaking News On - Laura mittmann - Page 1 : comparemela.com

Agomab Therapeutics NV: Agomab Raises Additional $40 5 Million Through Series B Extension Bringing Total Amount to $114 Million

Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors Funding will support next stage of clinical and corporate development

Kostenloser wertpapierhandelLaura mittmannTim knotnerusThomas wynnMichael vincentRedmile groupTrophic communicationsPfizer breakthrough growth initiativeWalleye capitalAsabys partnersVice presidentInflammation immunology discovery biologyScientific advisoryChief executive officerOrigo biopharmaSenior vice president

Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy

Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesUniversity of california davisCraig mcdonaldPaolo betticaEugenio mercuriLaura mittmannJacob vergheseSanta lucia foundationDrug administrationDepartment of pediatricsItalfarmaco groupTrophic communicationsCatholic universityDuchenne muscular dystrophyChief medical officer

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors

United statesFrance generalBayern kapital gmbAndera croissanceMichael wackerWachstumsfonds bayernBayern kapitalThomas hankeKostenloser wertpapierhandelLaura mittmannBaker mckenzie julia braunDominik schumacherEuropean life sciencesPartner at fundTrophic communicationsBandera co

CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of

Kostenloser wertpapierhandelCatalym gmbPhil lhuillierIgnacio melero centerWorld health organizationInternational nonproprietary nameTrophic communicationsDifferentiation factorTed human effectorIgnacio meleroAdvanced medical researchPrincipal investigatorEugen leoChief medical officerPhill huillierGrowth differentiation

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

Press release content from Business Wire. The AP news staff was not involved in its creation.

Catalym gmbPhil lhuillierIgnacio melero centerWorld health organizationInternational nonproprietary nameTrophic communicationsDifferentiation factorIgnacio meleroAdvanced medical researchPrincipal investigatorEugen leoChief medical officerPhill huillierGrowth differentiationLaura mittmannCatalym gmbh